Q2 2025 · 13F-HR
Atle Fund Management ABholdings as filed
Filed 2025-07-14 · accession 0001381843-25-000006
$233.7M
Reported value
37
Positions
2025-06-30
Period end
The Brief · Atle Fund Management AB · Q2 2025
AI · grounded in 13F
Atle Fund Management AB established a new position in Eli Lilly & Co LLY valued at $30.2M. The fund also initiated new stakes in AbbVie Inc ABBV for $16.1M and Boston Scientific Corp BSX for $13.6M. Other new additions include Neurocrine Biosciences Inc NBIX, Merck & Co. Inc MRK, and Stryker Corporation SYK. The fund ended the period with 37 positions and total AUM of $233.7M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 532457108 | LLY | Eli Lilly & Co | $30.2M | 12.9% | 38,721 | Common | SOLE |
| 00287Y109 | ABBV | AbbVie Inc | $16.1M | 6.91% | 86,933 | Common | SOLE |
| 101137107 | BSX | Boston Scientific Corp | $13.6M | 5.80% | 126,185 | Common | SOLE |
| 64125C109 | NBIX | Neurocrine Biosciences Inc | $11.1M | 4.75% | 88,392 | Common | SOLE |
| 58933Y105 | MRK | Merck & Co. Inc | $11.0M | 4.71% | 139,172 | Common | SOLE |
| 863667101 | SYK | Stryker Corporation | $10.9M | 4.65% | 27,466 | Common | SOLE |
| 92532F100 | VRTX | Vertex Pharmaceuticals Inc | $10.8M | 4.64% | 24,328 | Common | SOLE |
| 46120E602 | ISRG | Intuitive Surgical Inc | $10.1M | 4.32% | 18,559 | Common | SOLE |
| 883556102 | TMO | Thermo Fisher Scientific Corp | $9.8M | 4.21% | 24,266 | Common | SOLE |
| 03073E105 | COR | Cencora Inc | $9.4M | 4.04% | 31,466 | Common | SOLE |
| 375558103 | GILD | Gilead Sciences Inc | $8.1M | 3.47% | 73,165 | Common | SOLE |
| 10806X102 | BBIO | Bridgebio Pharma Inc | $7.1M | 3.06% | 165,480 | Common | SOLE |
| 031162100 | AMGN | Amgen Inc | $6.7M | 2.86% | 23,894 | Common | SOLE |
| G01767105 | ALKS | Alkermes PLC | $6.5M | 2.78% | 227,224 | Common | SOLE |
| 07725L102 | ONC | BeiGene Ltd | $5.9M | 2.53% | 24,386 | Common | SOLE |
| 604749101 | MIRM | Mirum Pharmaceuticals Inc | $5.4M | 2.33% | 106,912 | Common | SOLE |
| 902673102 | UFPT | UFP Technologies Inc | $5.3M | 2.29% | 21,886 | Common | SOLE |
| 14149Y108 | CAH | Cardinal Health Inc | $4.5M | 1.93% | 26,797 | Common | SOLE |
| 28176E108 | EW | Edwards Lifesciences Corp | $4.5M | 1.92% | 57,360 | Common | SOLE |
| 925050106 | VRNA | VERONA PHARMA PLC - ADR | $4.5M | 1.91% | 47,100 | Common | SOLE |
| 252131107 | DXCM | Dexcom Inc | $4.4M | 1.90% | 50,872 | Common | SOLE |
| 450056106 | IRTC | iRhythm Technologies Inc | $3.9M | 1.67% | 25,302 | Common | SOLE |
| 834203309 | SLNO | Soleno Therapeutics Inc | $3.4M | 1.45% | 40,532 | Common | SOLE |
| N5749R100 | 2GH | Merus N.V. | $3.2M | 1.35% | 59,889 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION Medicines Inc | $3.0M | 1.30% | 82,275 | Common | SOLE |
| N62509109 | NAMS | NewAmsterdam Pharma Co NV | $2.8M | 1.22% | 157,223 | Common | SOLE |
| 501147102 | KRYS | Krystal Biotech, Inc | $2.8M | 1.19% | 20,158 | Common | SOLE |
| 413197104 | HRMY | HARMONY BIOSCIENCES HLDGS IN | $2.7M | 1.17% | 86,274 | Common | SOLE |
| 05280R100 | AUTL | Autolus Therapeutics PLC | $2.5M | 1.08% | 1,105,461 | Common | SOLE |
| 91324P102 | UNH | Universal Health Services Inc | $2.5M | 1.06% | 13,727 | Common | SOLE |
| 589492107 | MREO | Mereo Biopharma Group PLC | $2.1M | 0.89% | 764,901 | Common | SOLE |
| 86627T108 | SMMT | Summit Therapeutics Inc | $2.0M | 0.84% | 92,737 | Common | SOLE |
| 03940C100 | ACLXGBX | Arcellx Inc | $1.7M | 0.73% | 25,732 | Common | SOLE |
| 055477103 | BCAX | BICARA THERAPEUTICS INC | $1.4M | 0.59% | 147,380 | Common | SOLE |
| 254604101 | IRON | Disc medicine inc | $1.3M | 0.56% | 24,652 | Common | SOLE |
| 21833P301 | CRBP | Corbus Pharmaceuticals Holding | $1.2M | 0.52% | 175,582 | Common | SOLE |
| 47103J105 | JANX | Janux Therapeutics Inc | $1.2M | 0.49% | 49,820 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.